Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 11/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR1F | P30939 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230263 | 0.87 | HTR2C (0.42) | CALCRLOPRL1HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5101442 | 0.86 | HTR2C (0.41) | CALCRLHTR2AHTR2CHTR2B | |
| SCHEMBL3655076 | 0.82 | CHRM3 (0.51) | CHRM2CHRM3OPRL1OPRM1OPRK1 | |
| SCHEMBL12788175 | 0.79 | HTR5A (0.41) | OPRL1OPRM1OPRK1 | |
| SCHEMBL1700379 | 0.78 | CHRM2 (0.50) | CHRM2CHRM3CALCRLACHE | |
| SCHEMBL2966935 | 0.73 | PARP1 (0.47) | CALCRLHTR2AHTR2CHTR2B | |
| SCHEMBL13885027 | 0.73 | HTR5A (0.44) | OPRL1 | |
| SCHEMBL15759800 | 0.73 | HTR5A (0.41) | OPRL1 | |
| SCHEMBL30231387 | 0.73 | CALCRL (0.45) | CALCRLPARP2 | |
| Hydrochloric Acid SCHEMBL3882535 | 0.72 | PARP1 (0.46) | CALCRLHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952014-B2 | Pyrimidine derivatives which are CGRP—antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-20120088755-A1 | Novel Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088755-A1 | Novel Compounds | SLC26A4, F12, SLCO1B3 | CHRM2 145/4885CHRM3 434/4885CALCRL 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.